Subcutaneous Immunoglobulin (SCIG) from Takeda.
Cuvitru is a 20% SCIG product from Takeda. Like other SCIG products, it allows self-administration at home with stable IgG levels and excellent tolerability.
Cuvitru is FDA-approved for the following indications:
Cuvitru is administered subcutaneously weekly or every two weeks via self-infusion. Training is provided by an infusion nurse during the early weeks of therapy.
The manufacturer offers a patient support program — Takeda OnePath — that can help with insurance navigation, copay assistance for eligible patients, nursing support, and ongoing education. More information is available at https://www.takedapatientsupport.com.
Treatment with Cuvitru is initiated and monitored by Dr. McNeil. Prior authorizations are handled in-house — patients are not asked to navigate insurance approvals on their own. Administration logistics are coordinated by the office team based on the route of therapy and patient preference.
Important safety note: This page is not a substitute for the FDA prescribing information. Risks, contraindications, drug interactions, and required monitoring vary by patient. The official manufacturer website (https://www.cuvitru.com) provides the most current full prescribing and safety information. Treatment decisions and monitoring are individualized — please discuss with Dr. McNeil whether Cuvitru is appropriate for your situation.
Donald L. McNeil, MD · Board Certified in Allergy & Immunology and Internal Medicine
This page is provided for educational purposes only and is not medical advice. If you have an emergency, call 911.